NCT02909439View on ClinicalTrials.gov

Quality of Recovery After Reversal With Neostigmine or Sugammadex.

PHASE4CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

November 9, 2017

Study Completion Date

February 28, 2018

Conditions
Incomplete Reversal of Neuromuscular Block
Interventions
DRUG

Sugammadex

Sugammadex will be given for reversal of neuromuscular blockade.

DRUG

Neostigmine

Neostigmine will be given for reversal of neuromuscular blockade.

Trial Locations (1)

11794

Stony Brook University Hospital, Stony Brook

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Stony Brook University

OTHER

NCT02909439 - Quality of Recovery After Reversal With Neostigmine or Sugammadex. | Biotech Hunter | Biotech Hunter